ANRO
Alto NeuroscienceCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bullish view is that the March financing and roughly $275 million pro forma cash position buy enough runway to let ALTO-207, ALTO-300, and ALTO-100 reset sentiment after the ALTO-101 setback, with ALTO-207 now the lead value driver and potentially the clearest rerating path [#8-K-2026-04-01] [#10-K-2026-03-16].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.7.
What can break
ALTO-101 failed to hit statistical significance on primary EEG and cognitive endpoints, reducing pipeline breadth.
Momentum
90
Value
41
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $34.80
Why
Momentum90 · Δ7d +0.7
Value41 · Δ7d -0.1
Sentiment37 · Δ7d -6.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendImproving
Δ7d
+0.7
Δ21d
+29.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
37
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
-2.8
Why this grade
Composite grade C. Momentum 90.4 / Value 41.1 / Sentiment 37.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$966.49M
Beta
-
Shares Out
35.09M
P/E (TTM) · Derived
-12.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.26
Rev YoY
-
EPS YoY
+42.2%
Gross Margin
-
Op Margin
-
Net Debt
-$152.53M
Current Ratio
20.52
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology